March 21st 2023
A genetic analysis indicates that multi-ancestry polygenic risk scores may be “potentially useful” in detecting risk of aggressive prostate cancer in patients of African ancestry, according to an expert from the University of Southern California.
March 14th 2023
Novel PSMA-TRT-based Triplet Regimen Appears Effective in Prostate CancerDecember 2nd 2022
All patients with chemo-naïve metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy.
PSMA Remains ‘Relevant’ But Needs to Be ‘Improved Upon’ for Treating Prostate CancerDecember 1st 2022
“With more potent agents, can we actually cure patients [with prostate cancer]? I'm not so sure about that…because of heterogeneity,” said an expert from NewYork-Presbyterian – Weill Cornell Medical Center in New York City. “So we'll see. But I think with combinations, maybe someday we're going to be able to get there.”
More Research is Needed to Determine How to Integrate Theranostics With Standard Therapies for Localized Prostate Cancer, Says ExpertDecember 1st 2022
Theranostics may fill an unmet need for a group of patients with high-risk localized prostate cancer, but more research is needed to identify how oncology providers can integrate it with the standard treatments, according to an expert from the University of Texas MD Anderson Cancer Center.
Addition of Rezvilutamide to ADT Improves OS and rPFS Vs Bicalutamide/ADT in Hormone-Sensitive Prostate CancerNovember 30th 2022
Rezvilutamide with androgen-deprivation therapy yielded improved overall survival and radiographic progression-free survival compared with bicalutamide and androgen-deprivation therapy in patients with high-volume metastatic hormone-sensitive prostate cancer.
2022 ASTRO Round-Up: A Shift Toward a New Standard of Care in Radiotherapy and Reducing Cancer Treatment DurationNovember 27th 2022
From shortening treatment duration without compromising efficacy in breast and prostate cancer to improving quality of life, experts share the main takeaways from the 2022 ASTRO Annual Meeting.
Neeraj Agarwal, MD, Discusses Potential Link Between ctDNA, AR Aberrations, and Survival in mCSPCNovember 26th 2022
The appearance of circulating tumor DNA and androgen receptor aberrations yielded lower overall survival rates for patients with metastatic castration-sensitive prostate cancer during the phase 3 TITAN trial, according to Agarwal, MD.
Benjamin H. Lowentritt, MD, FACS, Discusses Future Analyses for the Phase 3 SPOTLIGHT Trial in Recurrent Prostate CancerNovember 18th 2022
Future focuses following the phase 3 SPOTLIGHT trial will include identifying sites of recurrence and different intensity levels for 18F-rhPSMA-7.3 in suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.
Benjamin H. Lowentritt, MD, FACS, Details Rationale for an Analysis Assessing How Clinical Factors Influence 18F-rhPSMA-7.3 Detection in Suspected Recurrent Prostate CancerNovember 11th 2022
The goal of the analysis of the phase 3 SPOTLIGHT trial was to evaluate how clinical factors impact 18F-rhPSMA-7.3 detection rates in a population of patients with suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.
PSMA-PET SUVmean Predictive of Favorable Response to 177Lu-PSMA-617 Than Cabazitaxel in mCRPCNovember 10th 2022
According to findings from a biomarker analysis of the phase 2 TheraP trial, mean standardized uptake value of PSMA-PET predicted favorable responses to 177Lu-PSMA-617 compared with cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Benjamin H. Lowentritt, MD, FACS, Discusses How 18F-rhPSMA-7.3 PET Expands the Armamentarium for Suspected Recurrent Prostate CancerNovember 8th 2022
Novel PSMA-targeting PET ligand 18F-rhPSMA-7.3 adds to the recurrent prostate cancer armamentarium, according to Benjamin H. Lowentritt, MD, FACS.
Darolutamide Plus ADT and Docetaxel Improves Quality of Life Vs Placebo in mHSPCOctober 31st 2022
Quality of life data from the phase 3 ARASENS study highlighted how early treatment intensification with darolutamide plus standard androgen deprivation therapy and docetaxel improved patient-relevant end points compared with placebo in the management of metastatic hormone-sensitive prostate cancer.
Phuoc Tho Tran, MD, Examines Efficacy Data for SRT/Enzalutamide Vs Placebo in Advanced Prostate CancerOctober 31st 2022
At ASTRO 2022, Phuoc Tho Tran, MD, spoke about the potential benefit of combining salvage radiation therapy and enzalutamide vs placebo in patients with high-risk prostate-specific antigen–recurrent prostate cancer after radical prostatectomy.
Metastasis-Directed Therapy Plus Intermittent Hormone Therapy Improves PFS in Oligometastatic Prostate CancerOctober 29th 2022
The addition of metastasis-directed therapy to intermittent hormone therapy appeared to improve survival in patients with oligometastatic prostate cancer, according to early data from the phase 2 EXTEND trial.
Post-Operative iSRT Plus Degarelix Yields Improved MFS in Prostate Cancer With Elevated PSAOctober 28th 2022
Patients with prostate cancer who experienced an increase in prostate-specific antigen level after radical prostatectomy appeared to benefit from a short course of androgen deprivation therapy after post-operative immediate salvage radiotherapy.
High Detection Rates Achieved With 18F-rhPSMA-7.3 PET in Recurrent Prostate CancerOctober 26th 2022
Data from the phase 3 SPOTLIGHT trial indicated that 18F-rhPSMA-7.3 PET yielded a positive detection rate in patients with recurrent prostate cancer, and increased along with prostate-specific antigen level.
Cabazitaxel at Lowered Dose, Increased Frequency Reduces Neutropenic Complications in Older Patients With mCRPCOctober 25th 2022
Based on findings from the phase 3 CABASTY trial, a fixed 16 mg/m2 dose of cabazitaxel every 2 weeks vs 25 mg/m2 every 3 weeks reduced neutropenic complications in elderly patients with mCRPC.
Conventional Radiotherapy and 5 Fraction SBRT Produce Comparable Toxicity in Prostate CancerOctober 24th 2022
According to findings from the phase 3 PACE-B trial, genitourinary and gastrointestinal toxicities were similar among patients with prostate cancer receiving conventionally fractioned or moderately hypofractionated radiotherapy and stereotactic body radiotherapy.
Despite Presenting With More Aggressive Disease, Black Vs White Men With Prostate Cancer Have Improved Outcomes Following RadiotherapyOctober 20th 2022
A meta-analysis found Black men who undergo radiotherapy for localized prostate cancer have better outcomes in terms of biochemical recurrence, distant metastases, and prostate cancer-specific mortality than White men despite presenting with more aggressive disease.
Talazoparib and Enzalutamide Combo Yields Meaningful rPFS Improvement in mCRPC Regardless of HRR StatusOctober 5th 2022
The phase 3 TALAPRO-2 study met the primary end point of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations following treatment with a combination of talazoparib and enzalutamide.
Phase 3 TRITON3 Trial Meets Primary End Point of Radiographic PFS With Rucaparib for mCRPCOctober 3rd 2022
Results from the phase 3 TRITON3 trial demonstrated that radiographic progression-free survival was significantly improved when patients with metastatic castration-resistant prostate cancer were treated with rucaparib monotherapy vs physician’s choice.
PSA Levels at 8 Months Predict Survival Outcomes With ADT Combinations in mCRPCOctober 3rd 2022
A recent analysis of data from the phase 3 PEACE-1 study reveals a correlation between 8-month prostate-specific antigen levels and survival outcomes in patients with metastatic castration-sensitive prostate cancer who are treated with systemic therapy regimens that include androgen deprivation therapy.
Despite Improving Responses, Pembrolizumab/Olaparib Fails to Improve Survival in mCRPCSeptember 29th 2022
Results from the phase 3 KEYLYNK-010 study showed that treatment with pembrolizumab and olaparib did not result in a statistically significant improvement in survival despite yielding higher responses compared with novel hormonal agents in patients with previously treated prostate cancer.
Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-upSeptember 22nd 2022
Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate CancerSeptember 18th 2022
Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.